Targeted α-therapy in non-prostate malignancies

Progress in unraveling the complex biology of cancer, novel developments in radiochemistry, and availability of relevant α-emitters for targeted therapy have provided innovative approaches to precision cancer management. The approval of 223 Ra dichloride for treatment of men with osseous metastatic...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2021-12, Vol.49 (1), p.47-53
Main Authors: Jadvar, Hossein, Colletti, Patrick M.
Format: Article
Language:English
Subjects:
Antigens
Breast
Cardiology
Dichlorides
Emitters
Humans
Imaging
Leukemia
Male
Medicine
Medicine & Public Health
Melanoma
Metastases
Myeloma
Neuroendocrine tumors
Nuclear Medicine
Oncology
Orthopedics
Pancreas
Pharmaceuticals
Prostate cancer
Prostatic Neoplasms
Radiochemistry
Radioisotopes
Radiology
Radiopharmaceuticals
Review Article
Theragnostic
Therapy
Urinary bladder
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Progress in unraveling the complex biology of cancer, novel developments in radiochemistry, and availability of relevant α-emitters for targeted therapy have provided innovative approaches to precision cancer management. The approval of 223 Ra dichloride for treatment of men with osseous metastatic castrate-resistant prostate cancer unleashed targeted α-therapy as a safe and effective cancer management strategy. While there is currently active research on new α-therapy regimens for prostate cancer based on the prostate-specific membrane antigen, there is emerging development of radiopharmaceutical therapy with a range of biological targets and α-emitting radioisotopes for malignancies other than the prostate cancer. This article provides a brief review of preclinical and first-in-human studies of targeted α-therapy in the cancers of brain, breast, lung, gastrointestinal, pancreas, ovary, and the urinary bladder. The data on leukemia, melanoma, myeloma, and neuroendocrine tumors will also be presented. It is anticipated that with further research the emerging role of targeted α-therapy in cancer management will be defined and validated.
ISSN:1619-7070
1619-7089
1619-7089
DOI:10.1007/s00259-021-05405-0